Table 1.
Clinical characteristics and medical treatment according to quartiles of peak C-reactive protein
| Quartile of C-reactive protein, (Range mg/l) | |||||
| 1st (n = 85) (0.05–5.3) |
2nd (n = 82) (5.4–19.6) |
3rd (n = 84) (19.7–64.5) |
4th (n = 83) (64.6–304) |
p | |
| Female, % | 35 | 42 | 27 | 29 | 0.2 |
| Age, mean (range) |
70 (41–91) |
70 (27–90) |
73 (43–97) |
75 (53–92) |
0.02 |
| Waist circumference, cm (SD) | 95 (12) |
96 (13) |
96 (12) |
95 (11) |
1.0 |
| Current smokers, % | 19 | 18 | 25 | 22 | 0.7 |
| Hypertension, % | 29 | 44 | 35 | 45 | 0.1 |
| Diabetes, % | 16 | 24 | 26 | 12 | 0.07 |
| Previous AMI, % | 25 | 30 | 28 | 25 | 0.8 |
| Previous stroke, % | 11 | 15 | 18 | 13 | 0.6 |
| Previous heart failure, % | 11 | 15 | 8 | 18 | 0.2 |
| Atrial fibrillation | 16 | 16 | 23 | 23 | 0.5 |
| GFR, mean (SD) | 85 (33) |
84 (36) |
81 (35) |
66 (35) |
0.004 |
| TnT peak, median μg/L | 0.49 (0.21–1.26) |
1.1 (0.33–2.64) |
1.9 (0.92–5.18) |
4.0 (2.02–7.36) |
<0.0005 |
| LDL, mean (SD) | 3.5 (1.2) |
3.3 (0.9) |
3.2 (0.9) |
3.2 (1.3) |
0.3 |
| Clinical heart failure, during hospitalization, % | 18 | 16 | 30 | 62 | <0.0005 |
| PCI, % | 31 | 32 | 21 | 12 | 0.009 |
| CABG, % | 19 | 11 | 12 | 11 | 0.4 |
| LMWH or warfarin in hospital, % | 94 | 88 | 89 | 80 | 0.04 |
| Aspirin, at admission, % | 41 | 55 | 45 | 43 | 0.3 |
| Clopidogrel, at discharge, % | 62 | 61 | 40 | 16 | <0.005 |
| Statins, at discharge, % | 65 | 68 | 53 | 42 | 0.004 |
| ACE inhibitors or ARBs, at discharge, % | 36 | 49 | 49 | 61 | 0.02 |
| Betablockers, at discharge, % | 89 | 87 | 87 | 87 | 0.9 |
| Thrombolysis | 11 | 24 | 26 | 36 | 0.002 |